Camille Abboud

Medicine & Life Sciences

1. Acute Myeloid Leukemia 100%
2. Bone Marrow 72%
3. Stem Cells 59%
4. plerixafor octahydrochloride 42%
5. Allogeneic Cells 42%
6. Cytarabine 40%
7. Transplants 37%
8. Stem Cell Transplantation 37%
9. Granulocyte Colony-Stimulating Factor 36%
10. GATA2 Deficiency 33%
11. Leukemia 32%
12. Cytokines 31%
13. Decitabine 30%
14. Granulocyte-Macrophage Colony-Stimulating Factor 30%
15. Cell Line 28%
16. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25%
17. Autologous Transplantation 25%
18. Tissue Donors 25%
19. Therapeutics 23%
20. Graft vs Host Disease 23%
21. Cell Transplantation 22%
22. Neutrophils 22%
23. Stromal Cells 21%
24. Granulocyte-Macrophage Progenitor Cells 20%
25. Carmustine 20%
26. Drug Therapy 20%
27. Peripheral Blood Stem Cells 20%
28. Myelodysplastic Syndromes 19%
29. Hematopoietic Stem Cells 19%
30. Progression-Free Survival 19%
31. Etoposide 19%
32. HL-60 Cells 19%
33. Chemokines 18%
34. Granulocytes 17%
35. Stem Cell Factor 17%
36. Colony-Stimulating Factors 17%
37. Interleukin-1 17%
38. Lymphoma 17%
39. Blast Crisis 17%
40. B-Lymphoid Precursor Cells 16%
41. Hodgkin Disease 16%
42. Safety 16%
43. Cladribine 16%
44. Integrins 16%
45. Eosinophils 16%
46. Intercellular Signaling Peptides and Proteins 16%
47. Hematopoietic Stem Cell Transplantation 15%
48. Survival 15%
49. Neoplasms 15%
50. Simplexvirus 15%